Matinas BioPharma Holdings (MTNB) Current Assets (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Current Assets of $2.8 million for Q1 2026, down 62.7% year-over-year from $7.5 million in Q1 2025, and down 30.92% quarter-over-quarter from $4.1 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Current Assets (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Current Assets for 14 consecutive years, with $2.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 62.7% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 62.7% YoY), while the FY2025 annual figure was $4.1 million, down 49.22% from the prior year.
- Current Assets slipped to $2.8 million in Q1 2026 per MTNB's latest filing, from $4.1 million in the prior quarter.
- Across five years, Current Assets topped out at $45.1 million in Q1 2022 and bottomed at $2.8 million in Q1 2026.
- Historically, Current Assets has averaged $18.8 million across 5 years, with a median of $15.3 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets slumped 63.52% — and 2025, when it retreated 26.65%.
- Matinas BioPharma Holdings' Current Assets stood at $34.5 million in 2022, then tumbled by 54.99% to $15.5 million in 2023, then plunged by 48.37% to $8.0 million in 2024, then sank by 49.22% to $4.1 million in 2025, then tumbled by 30.92% to $2.8 million in 2026.
- Business Quant data shows MTNB's Current Assets at $2.8 million in Q1 2026, $4.1 million in Q4 2025, and $5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 1.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.14 Mn |
| Mar 31, 2026 | 2.82 Mn |
| Dec 31, 2025 | 4.08 Mn |
| Sep 30, 2025 | 5.65 Mn |
| Jun 30, 2025 | 7.27 Mn |
| Mar 31, 2025 | 7.55 Mn |
| Dec 31, 2024 | 8.03 Mn |
| Sep 30, 2024 | 11.74 Mn |
| Jun 30, 2024 | 15.29 Mn |
| Mar 31, 2024 | 10.29 Mn |
| Dec 31, 2023 | 15.54 Mn |
| Sep 30, 2023 | 19.99 Mn |
| Jun 30, 2023 | 24.00 Mn |
| Mar 31, 2023 | 28.21 Mn |
| Dec 31, 2022 | 34.53 Mn |
| Sep 30, 2022 | 37.10 Mn |
| Jun 30, 2022 | 41.92 Mn |
| Mar 31, 2022 | 45.12 Mn |
| Dec 31, 2021 | 50.99 Mn |
| Sep 30, 2021 | 56.48 Mn |